EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of acute hepatitis c virus with recombinant interferon alpha 2b clinical trial



Treatment of acute hepatitis c virus with recombinant interferon alpha 2b clinical trial



Digestive Disease Week Abstracts & Itinerary Planner : Abstract No T1246



A clinical trial was carried out aimed at evaluating the efficacy and safety of interferon in a group of 13 patients with acute hepatitis C. The diagnosis was made according to biochemical criteria (alanine aminotransferase 2 times the normal value), serological criteria (presence of anti hepatitis virus antibodies), virological criteria (presence of RNA-HCV by PCR) and histological criteria. Treatment with recombinant interferon Alfa 2b 3 000 000 IU was indicated 3 times a week during 12 weeks. It was proved that 53.8 % finished the period of treatment with normal alanine aminotransferase and that at the end of follow-up 30.7% had a maintained biochemical and virological response. 4 patients (36.3%) of de 11 that concluded the follow-up had a normal histology in the evolutive hepatic biopsy and of them 2 had a maintained biochemical and virological response, which made us think they were cured. Interferon was well tolerated and only 38.5% of patients showed secondary manifestations of toxicity. It was observed a predominance of cephalalgia, fever, myalgia and arthralgias. We concluded that interferon should be used in patients with acute hepatitis C.

(PDF same-day service: $19.90)

Accession: 035980765

Download citation: RISBibTeXText

DOI: 10.1016/S0016-5085(03)82554-4



Related references

Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. American Journal of Gastroenterology 90(2): 263-269, 1995

Recombinant interferon alpha 2 b for treatment of protracted acute virus hepatitis b. Zeitschrift fuer Klinische Medizin (Berlin) 46(7): 501-503, 1991

A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. Journal of Hepatology 21(5): 831-836, 1994

Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: results of a randomized controlled clinical trial. Hepatology 19(1): 1-5, 1994

Therapy of non a non b c chronic hepatitis with recombinant alpha 2a interferon r ifn or lymphoblastoid alpha interferon 1 ifn a randomized controlled clinical trial final report. Journal of Interferon Research 11(SUPPL 1): S247, 1991

Recombinant alpha 2a interferon r ifn lymphoblastoid alpha interferon 1 ifn or no treatment for non a non b chronic active hepatitis cah a prospective randomized controlled trial. Hepatology 10(4): 637, 1989

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 49(6): 1847-1858, 2009

Recombinant alpha 2b interferon in acute hepatitis C: Results of the treatment and determination of anti-interferon antibodies. Biotecnologia Aplicada 14(4): 242-247, 1997

Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group. Journal of Hepatology 11 Suppl 1: S31-S35, 1990

Alpha 2 recombinant interferon in the treatment of chronic hepatitis delta virus (HDV) hepatitis. Progress in Clinical and Biological Research 234: 299-303, 1987

Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy Group. Journal of Viral Hepatitis 1(1): 55-63, 1994

Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B. Hepato-Gastroenterology 45(24): 2282-2294, 1999

Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 12(6): 1266-1270, 1990

Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clinical Therapeutics 24(10): 1627-1635, October, 2002